Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) is pleased to announce that it has closed its fully subscribed private placement offering (the “Offering”) of common shares of the Company (the “Shares”). The Company raised aggregate gross proceeds of $3,000,000 through the issuance of 7,500,000 Shares at a price of C$0.40 per Sh ...

Asian healthcare-focused private equity firm Quadria Capital is considering selling its minority stake in Indian topical pharmaceutical company Encube Ethicals Pvt, people familiar with the matter said https://t.co/typwsQAk7F ...

[Applause] [Music] Good afternoon. Assume you are on a plane about to skydive. You know, how would you react. Would you be worried. Would you be glad.You know, I would be worried. I'd say not in a million years I'm not jumping off this plane. And that's exactly what I did when I said I wanted to go play nationals for India at the age of 37.People looked at me and they said are you crazy. What are you trying to do here. And then I said why not you know let me take the first step.That's exactly where this sta ...

Next is Yashi Arian and she is an international graduate student pursuing an MS in pharmaceutics at Northeastern University and she is passionate about advancing her technical skills and knowledge in the pharmaceutical industry. She's also the current graduate student ambassador for the pharmaceutics program at Nor Eastern. Please join me in welcoming Yashiarian.just like this. Wow. Okay.I just translate sorry about that. I'm not giving these presentations. Okay.So since the talk is about passion, I'm going ...

A company that has Donald Trump Jr. on its board debuted a new service to help pharmaceutical companies launch direct sales platforms, one week after President Donald Trump demanded that drugmakers create similar systems https://t.co/ExB9UpSQlI ...

Eli Lily reporting uh second quarter results just a few minutes ago. The stock under pressure uh after trial results from its oral weight loss drug disappointed investors. Joining us now, David Ricks, chairman and CEO of Eli Lily.Uh also on set is our own Angelica Peebles. And you you we need Thank you for coming on uh this morning by the way. Uh uh David, and I'd like to hear your uh analysis of what's happening cuz I don't know, 12% if you're not over 300 lb, that's about what I'd want to probably lose.So ...

Company Performance - Eli Liy's market capitalization has increased by approximately 860% since the current CEO took office [1] - The stock price is up a little bit more than 1,000% [1] Drug Development & Market - Eli Liy is the world's most valuable pharmaceutical company and a leader in the GLP-1 drug market [1] - GLP-1 drugs have become increasingly popular [1] - Eli Liy says it has a pill, eliminating the need for needles [1] - Eli Lily's experimental pill appears to work as well as the injected drug [2]

Fizer reporting a beat on revenue and earnings for its second quarter, but the pharmaceutical manufacturer is facing new hurdles with tariff threats and calls from President Trump to lower prices. Our own Julie Hyman and senior health reporter Anelie Kamlani spoke with the CEO about cost cutting efforts and the future of the firm. >> I would call it more productivity enhancement and margin expansion.Uh we do that by implementing three things. One it is focus. So we stop doing things that they are not that i ...

Financial Data and Key Metrics Changes - Net Asset Value (NAV) increased by $252 million from the first quarter, primarily driven by positive performance in CVI, offset by decreases in auto service [5] - The investment funds ended down approximately 0.5% for the quarter, primarily driven by gains in the consumer cyclical sector, offset by broad market and refining hedges [6] - The holding company ended the quarter with $1.1 billion in cash and cash equivalents, and an additional $700 million of cash at the funds [10] Business Line Data and Key Metrics Changes - Energy segment consolidated EBITDA was negative $24 million for Q2 2025 compared to $103 million in Q2 2024, negatively impacted by unfavorable RINs valuation and reduced throughput volumes [14] - Automotive service revenues decreased by $8 million compared to the prior year quarter, but same-store revenues improved from a 5% decline to 1% growth in May and June [15] - Real estate's Q2 2025 adjusted EBITDA decreased by $2 million compared to the prior year quarter, following the sale of a successful country club investment [17] - Food packaging's adjusted EBITDA decreased by $9 million for Q2 2025 due to lower volume and higher manufacturing inefficiencies [18] Market Data and Key Metrics Changes - CVI's share price increased by 38%, contributing to a $561 million increase in NAV from the first quarter [5] - The auto service division showed a positive trajectory in revenue growth, indicating a potential turnaround [15] Company Strategy and Development Direction - The company is focusing on maintaining liquidity to capitalize on opportunities within and outside existing operating segments, with a total liquidity of $3.5 billion at the holding company and $1.1 billion at subsidiaries [19] - The company plans to redeploy capital from the successful country club sale to new opportunities, aiming to replicate past successes [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the resolution of outstanding litigation related to small refinery exemptions, which could remove a $548 million liability [6] - The company sees considerable value creation potential in its portfolio, particularly in electric utilities and digital businesses [11][12] Other Important Information - CVI's CEO, Dave Lamp, will retire at year-end, with Mark Pytosh being promoted as his replacement [6] - The Board maintained the quarterly distribution at $0.50 per depositary unit [10] Q&A Session Summary Question: Regarding the decrease in cash balance at the holding company level - The decrease was primarily due to interest payments and LP distributions, with some impact from the CVR repurchase of about $32 million [21]

According to recent data, the prices that Americans have been paying for brandame drugs are more than three times the price other similar similarly developed nations pay. The president is determined to solve this problem and took further action today. He has signed 17 letters to pharmaceutical companies CEOs and I would like to read you one of these letters to the CEO of Eli Liy.On May 12th, 2025, I signed an executive order delivering most favored nation prescription drug pricing to American patients to st ...